Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets
Modified release of furosemide from tablet formulations is preferred by patients, because of physiological problems, acute diuresis being the most serious, compared to the forms designed for immediate release. With this in view, we aimed at achieving furosemide’s longer gastric retention and waste m...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2020-03-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2020-0010 |
| _version_ | 1797848616599027712 |
|---|---|
| author | Vlachou Marilena Geraniou Efthymia Siamidi Angeliki |
| author_facet | Vlachou Marilena Geraniou Efthymia Siamidi Angeliki |
| author_sort | Vlachou Marilena |
| collection | DOAJ |
| description | Modified release of furosemide from tablet formulations is preferred by patients, because of physiological problems, acute diuresis being the most serious, compared to the forms designed for immediate release. With this in view, we aimed at achieving furosemide’s longer gastric retention and waste minimization by preparing matrix and compression coated tablets incorporating different grades of Eudragit® and poly(ethylene oxide) (PEO), polyvinylpyrrolidone (PVP) and lactose monohydrate. Dissolution profiles of the new formulations were compared with that of the main stream drug Lasix®, 40 mg tablets. The results indicate that the use of Eudragit® in conjunction with either PVP or lactose monohydrate led to a slower release rate in the intestinal fluids compared to Lasix®. Moreover, furosemide release in the intestinal pH from matrix tablets and compression coated tablets was not noticeably different. Formulations incorporating PEO led to sustained release, in intestinal fluids, which depended on the molecular weight of PEO. |
| first_indexed | 2024-04-09T18:30:25Z |
| format | Article |
| id | doaj.art-01314f56071e4276913867332383b6c3 |
| institution | Directory Open Access Journal |
| issn | 1846-9558 |
| language | English |
| last_indexed | 2024-04-09T18:30:25Z |
| publishDate | 2020-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj.art-01314f56071e4276913867332383b6c32023-04-11T17:07:20ZengSciendoActa Pharmaceutica1846-95582020-03-01701496110.2478/acph-2020-0010acph-2020-0010Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tabletsVlachou Marilena0Geraniou Efthymia1Siamidi Angeliki2Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of AthensSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of AthensSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of AthensModified release of furosemide from tablet formulations is preferred by patients, because of physiological problems, acute diuresis being the most serious, compared to the forms designed for immediate release. With this in view, we aimed at achieving furosemide’s longer gastric retention and waste minimization by preparing matrix and compression coated tablets incorporating different grades of Eudragit® and poly(ethylene oxide) (PEO), polyvinylpyrrolidone (PVP) and lactose monohydrate. Dissolution profiles of the new formulations were compared with that of the main stream drug Lasix®, 40 mg tablets. The results indicate that the use of Eudragit® in conjunction with either PVP or lactose monohydrate led to a slower release rate in the intestinal fluids compared to Lasix®. Moreover, furosemide release in the intestinal pH from matrix tablets and compression coated tablets was not noticeably different. Formulations incorporating PEO led to sustained release, in intestinal fluids, which depended on the molecular weight of PEO.https://doi.org/10.2478/acph-2020-0010matrix tabletscompression coated tabletsfurosemideeudragit®poly(ethylene oxide)polyvinylpyrrolidone |
| spellingShingle | Vlachou Marilena Geraniou Efthymia Siamidi Angeliki Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets Acta Pharmaceutica matrix tablets compression coated tablets furosemide eudragit® poly(ethylene oxide) polyvinylpyrrolidone |
| title | Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets |
| title_full | Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets |
| title_fullStr | Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets |
| title_full_unstemmed | Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets |
| title_short | Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets |
| title_sort | modified release of furosemide from eudragits r and poly ethylene oxide based matrices and dry coated tablets |
| topic | matrix tablets compression coated tablets furosemide eudragit® poly(ethylene oxide) polyvinylpyrrolidone |
| url | https://doi.org/10.2478/acph-2020-0010 |
| work_keys_str_mv | AT vlachoumarilena modifiedreleaseoffurosemidefromeudragitsandpolyethyleneoxidebasedmatricesanddrycoatedtablets AT geraniouefthymia modifiedreleaseoffurosemidefromeudragitsandpolyethyleneoxidebasedmatricesanddrycoatedtablets AT siamidiangeliki modifiedreleaseoffurosemidefromeudragitsandpolyethyleneoxidebasedmatricesanddrycoatedtablets |